Craig-Hallum analyst Matt Hewitt maintained a Buy rating on OmniAb (OABI – Research Report) today. The company’s shares closed last Friday at $4.67.
According to TipRanks, Hewitt is an analyst with an average return of -1.5% and a 44.64% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Avid Bioservices, Inotiv, and Apyx Medical.
OmniAb has an analyst consensus of Strong Buy, with a price target consensus of $9.67, a 107.07% upside from current levels. In a report released on April 29, RBC Capital also maintained a Buy rating on the stock with a $7.00 price target.
OABI market cap is currently $547M and has a P/E ratio of -9.20.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OABI in relation to earlier this year. Most recently, in March 2024, Matthew W. Foehr, the President & CEO of OABI bought 243,613.00 shares for a total of $907,023.21.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OmniAb (OABI) Company Description:
Avista Public Acquisition Corp II is a blank check company.
